Actelsar HCT: Uses, Dosage & Side Effects
A fixed-dose combination of telmisartan (angiotensin II receptor blocker) and hydrochlorothiazide (thiazide diuretic) for the treatment of essential hypertension in adults
Actelsar HCT is a prescription combination medicine containing two active ingredients: telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. It is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is not adequately controlled with either telmisartan or hydrochlorothiazide alone. By combining two different mechanisms of blood pressure reduction, Actelsar HCT provides more effective and sustained blood pressure control, helping to reduce the risk of serious cardiovascular complications such as heart attack, stroke, and kidney disease.
Quick Facts: Actelsar HCT
Key Takeaways
- Actelsar HCT combines telmisartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) in a single tablet to treat high blood pressure in adults when monotherapy is insufficient.
- The medication must never be used during pregnancy as telmisartan can cause serious harm to the developing fetus, including kidney damage and reduced amniotic fluid. Women of childbearing potential should use effective contraception.
- Regular monitoring of kidney function, electrolytes (especially potassium, sodium, and magnesium), and blood pressure is essential during treatment to ensure safety and effectiveness.
- Actelsar HCT is taken once daily, with or without food. The full blood pressure-lowering effect typically develops within 4 to 8 weeks. Do not stop taking it without consulting your doctor, even if you feel well.
- Patients with diabetes or moderate-to-severe kidney impairment must not take Actelsar HCT together with aliskiren-containing medicines due to the risk of dangerous hypotension, hyperkalemia, and renal failure.
What Is Actelsar HCT and What Is It Used For?
Actelsar HCT belongs to a class of medicines known as fixed-dose combination antihypertensives. It combines two well-established blood pressure-lowering drugs into a single tablet: telmisartan, which is an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, which is a thiazide diuretic. Both of these drug classes have been extensively studied and recommended as first-line treatments for hypertension by major international guidelines, including the European Society of Hypertension (ESH), the American Heart Association (AHA), and the World Health Organization (WHO).
Telmisartan works by selectively blocking the angiotensin II type 1 (AT1) receptor. Angiotensin II is a powerful hormone produced by the renin-angiotensin-aldosterone system (RAAS) that causes blood vessels to constrict (narrow) and stimulates the release of aldosterone, a hormone that promotes sodium and water retention by the kidneys. By blocking the AT1 receptor, telmisartan prevents these effects, causing blood vessels to relax and widen (vasodilation), reducing sodium and water retention, and ultimately lowering blood pressure. Unlike ACE inhibitors, which also target the RAAS, ARBs like telmisartan do not interfere with the breakdown of bradykinin, which is why they are less likely to cause the persistent dry cough that is a well-known side effect of ACE inhibitors.
Hydrochlorothiazide works through a different and complementary mechanism. It acts on the distal convoluted tubule of the kidney, where it inhibits the sodium-chloride symporter (NCC). This inhibition reduces the reabsorption of sodium and chloride from the urine back into the bloodstream. As more sodium is excreted in the urine, water follows by osmosis, producing a diuretic (water-eliminating) effect. This reduces the volume of blood circulating in the body, which in turn lowers blood pressure. Over the longer term, hydrochlorothiazide also appears to reduce peripheral vascular resistance, contributing an additional blood pressure-lowering effect beyond simple volume reduction.
The rationale for combining these two agents is well-supported by clinical evidence. When telmisartan is used alone, it reduces blood pressure by relaxing blood vessels and reducing RAAS-mediated sodium retention. However, when the body senses lower blood pressure, it may activate compensatory mechanisms, including increased sodium retention through the kidneys. Hydrochlorothiazide counteracts this compensatory response by promoting sodium excretion. Conversely, hydrochlorothiazide alone can activate the RAAS as the body tries to compensate for fluid loss, but telmisartan blocks this activation. Together, the two drugs produce an additive or even synergistic blood pressure-lowering effect while partially cancelling out each other’s compensatory responses.
Essential hypertension, the condition for which Actelsar HCT is prescribed, is a chronic medical condition characterized by persistently elevated blood pressure (generally defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg). Hypertension is one of the most significant modifiable risk factors for cardiovascular disease worldwide. According to the WHO, approximately 1.28 billion adults aged 30 to 79 years worldwide have hypertension, yet only about 1 in 5 people with the condition have it under adequate control. Uncontrolled high blood pressure significantly increases the risk of heart attack, stroke, heart failure, chronic kidney disease, peripheral arterial disease, and vascular dementia.
Current international guidelines, including the 2023 ESH Guidelines and 2024 AHA/ACC Guidelines, recommend initiating combination therapy with two antihypertensive agents (preferably in a single pill) for most patients with hypertension, particularly those with blood pressure more than 20/10 mmHg above target. Single-pill combinations like Actelsar HCT improve adherence (patients are more likely to take one pill than two), provide complementary mechanisms of action, and achieve faster blood pressure control with fewer side effects compared with high-dose monotherapy.
What Should You Know Before Taking Actelsar HCT?
Contraindications
There are several conditions under which Actelsar HCT must not be used. Understanding these contraindications is essential for safe treatment.
- Hypersensitivity: Do not take Actelsar HCT if you are allergic to telmisartan, hydrochlorothiazide, or any other ingredient in the tablet. Cross-sensitivity with other sulfonamide-derived drugs is theoretically possible with hydrochlorothiazide, though clinically rare.
- Pregnancy (second and third trimesters): Actelsar HCT is strictly contraindicated during the second and third trimesters of pregnancy. Use during the first trimester is not recommended either. ARBs can cause fetal renal dysfunction, oligohydramnios (low amniotic fluid), skull ossification defects, and neonatal hypotension, renal failure, and death.
- Biliary obstructive disorders or severe hepatic impairment: Telmisartan is primarily eliminated through bile. Patients with biliary obstruction or severe liver impairment should not take this medication.
- Severe renal impairment: Patients with severely impaired renal function (creatinine clearance <30 mL/min) should not use Actelsar HCT, as hydrochlorothiazide may be ineffective and potentially harmful in this setting.
- Refractory hypokalemia or hypercalcemia: Do not use if you have persistently low potassium or high calcium levels that do not respond to treatment.
- Concurrent use with aliskiren in diabetic patients or those with moderate-to-severe renal impairment: Dual RAAS blockade with aliskiren-containing products significantly increases the risk of hypotension, hyperkalemia, and renal impairment.
Actelsar HCT must not be taken during pregnancy. If you discover you are pregnant while taking this medication, stop immediately and contact your doctor. Angiotensin II receptor blockers can cause serious and potentially fatal harm to the developing fetus, particularly affecting kidney development, amniotic fluid levels, and skull bone formation. Women of childbearing potential should use reliable contraception during treatment.
Warnings and Precautions
Before and during treatment with Actelsar HCT, talk to your doctor if any of the following conditions apply to you:
- Low blood pressure (hypotension): Symptomatic hypotension may occur, particularly in patients who are volume- or sodium-depleted (for example, those taking high-dose diuretics, on a salt-restricted diet, or experiencing diarrhea or vomiting). Volume depletion should be corrected before starting Actelsar HCT, or treatment should be initiated under close medical supervision.
- Kidney disease: In patients with impaired renal function, thiazide diuretics may precipitate azotemia (accumulation of nitrogen waste products). Regular monitoring of renal function is recommended. If progressive renal impairment becomes evident, reassessment of therapy is warranted.
- Renal artery stenosis: Patients with bilateral renal artery stenosis or stenosis in a solitary kidney are at increased risk of severe hypotension and renal failure when treated with agents that affect the RAAS.
- Liver disease: Telmisartan is mainly metabolized in the liver. Patients with hepatic impairment may have increased exposure to the drug. Use with caution and consider dose adjustment.
- Diabetes mellitus: Hydrochlorothiazide can impair glucose tolerance and may increase blood sugar levels. Dose adjustment of insulin or oral hypoglycemic agents may be necessary. Regular blood glucose monitoring is important.
- Gout or hyperuricemia: Hydrochlorothiazide can elevate serum uric acid levels and may precipitate gout attacks in susceptible individuals.
- Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia (low potassium), hyponatremia (low sodium), hypomagnesemia (low magnesium), and hypercalcemia (high calcium). Telmisartan tends to counterbalance the potassium-lowering effect of HCTZ, but monitoring remains essential. Symptoms of electrolyte disturbance include muscle cramps, fatigue, confusion, and irregular heartbeat.
- Systemic lupus erythematosus (SLE): Hydrochlorothiazide has been reported to activate or exacerbate systemic lupus erythematosus in rare cases.
- Eye conditions: In rare cases, hydrochlorothiazide can cause acute myopia and secondary angle-closure glaucoma. Symptoms include sudden onset of decreased visual acuity, eye pain, and eye redness, typically appearing within hours to weeks of starting the drug. Seek immediate medical attention if these symptoms develop.
- Skin cancer risk: Hydrochlorothiazide increases photosensitivity and has been associated with a slightly increased risk of non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) with cumulative, long-term use. Patients taking Actelsar HCT should limit exposure to sunlight and UV radiation, use adequate sun protection, and have regular skin examinations.
- Primary aldosteronism: Patients with primary aldosteronism generally do not respond to antihypertensive drugs acting through the renin-angiotensin system. Use of Actelsar HCT is not recommended in these patients.
Pregnancy and Breastfeeding
As noted above, Actelsar HCT is strictly contraindicated during pregnancy, particularly during the second and third trimesters, due to the risk of serious fetal harm from telmisartan. If pregnancy is detected, the medication must be discontinued as soon as possible. Women planning to become pregnant should be switched to alternative antihypertensive treatments that have an established safety profile during pregnancy, such as methyldopa, labetalol, or nifedipine, as recommended by major guidelines.
Both telmisartan and hydrochlorothiazide are excreted in breast milk. Hydrochlorothiazide passes into breast milk in small amounts, and at high doses may reduce milk production. Due to the potential for adverse effects in the nursing infant, breastfeeding is not recommended during treatment with Actelsar HCT. Your doctor can advise on suitable alternatives if you are breastfeeding or planning to breastfeed.
Driving and Operating Machinery
Actelsar HCT may occasionally cause dizziness or drowsiness, particularly at the start of treatment or when the dose is increased. If you experience these symptoms, avoid driving, operating machinery, or performing activities that require alertness until you know how the medication affects you. The risk of dizziness may be higher in hot weather or during physical exertion, as the diuretic component may increase fluid loss.
How Does Actelsar HCT Interact with Other Drugs?
Drug interactions with Actelsar HCT can be clinically important and may affect the safety or effectiveness of treatment. Both telmisartan and hydrochlorothiazide have distinct interaction profiles. It is essential to inform your prescribing doctor about all prescription medications, over-the-counter drugs, herbal supplements, and dietary supplements you are currently taking.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Aliskiren | Dual RAAS blockade increases risk of hypotension, hyperkalemia, and renal impairment | Contraindicated in patients with diabetes or renal impairment (eGFR <60); avoid in all others |
| ACE inhibitors (e.g., enalapril, ramipril) | Dual RAAS blockade with similar risks to aliskiren combination | Avoid concurrent use; if essential, strict monitoring of blood pressure, renal function, and potassium |
| Lithium | Both ARBs and thiazide diuretics reduce lithium excretion, increasing serum lithium to potentially toxic levels | Avoid combination if possible; if unavoidable, frequent lithium level monitoring is essential |
| NSAIDs (e.g., ibuprofen, naproxen, diclofenac) | Reduce the blood pressure-lowering effect of both components; increase risk of acute kidney injury, especially in dehydrated patients | Use with caution; ensure adequate hydration; monitor kidney function and blood pressure |
| Potassium supplements or potassium-sparing diuretics (e.g., spironolactone, amiloride) | Telmisartan can increase potassium levels; combined with potassium-raising agents, hyperkalemia risk increases significantly | Avoid unless specifically indicated; monitor serum potassium frequently |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Digoxin | Telmisartan may increase digoxin plasma concentrations by approximately 20%; HCTZ-induced hypokalemia increases digoxin toxicity risk | Monitor digoxin levels and serum potassium; adjust digoxin dose as needed |
| Corticosteroids (e.g., prednisolone) | May reduce the antihypertensive effect and enhance potassium loss caused by hydrochlorothiazide | Monitor blood pressure and potassium levels |
| Antidiabetic agents (insulin, oral hypoglycemics) | Hydrochlorothiazide may impair glucose tolerance, potentially requiring dose adjustment of diabetes medications | Monitor blood glucose more frequently after starting Actelsar HCT |
| Alcohol | May potentiate the orthostatic hypotensive effect of hydrochlorothiazide | Limit alcohol consumption; be cautious when standing up quickly |
| Cholestyramine and colestipol | Can reduce the absorption of hydrochlorothiazide from the gastrointestinal tract | Take Actelsar HCT at least 1 hour before or 4–6 hours after bile acid sequestrants |
Telmisartan is primarily metabolized by glucuronidation and does not undergo significant cytochrome P450 metabolism, which limits its potential for hepatic drug-drug interactions. However, it is a substrate for P-glycoprotein and may interact with drugs that affect this transporter. Hydrochlorothiazide is not significantly metabolized and is excreted largely unchanged by the kidneys, but its effects on electrolytes can influence the safety profile of many other drugs, particularly cardiac glycosides and antiarrhythmic agents.
What Is the Correct Dosage of Actelsar HCT?
Actelsar HCT is taken orally once daily. The tablets should be swallowed whole with water. It can be taken with or without food, though taking it consistently at the same time each day (preferably in the morning) helps maintain steady blood levels and supports adherence. The dose your doctor prescribes will depend on your current blood pressure level, any previous antihypertensive treatment you have tried, and your overall health status.
Adults
Standard Dose
Strength: Telmisartan 40 mg / Hydrochlorothiazide 12.5 mg
Frequency: Once daily
Administration: Oral, with or without food
This is the most commonly prescribed starting strength for patients who have not achieved adequate blood pressure control with telmisartan 40 mg monotherapy or hydrochlorothiazide 12.5 mg monotherapy.
Higher Dose Options
Telmisartan 80 mg / HCTZ 12.5 mg: For patients requiring additional blood pressure reduction with the ARB component.
Telmisartan 80 mg / HCTZ 25 mg: The maximum recommended combination dose. Used when maximal blood pressure reduction is needed. It is important not to exceed HCTZ 25 mg daily, as higher diuretic doses are associated with significantly increased metabolic side effects without proportionally greater blood pressure reduction.
It is generally recommended that patients be titrated on the individual components (telmisartan and hydrochlorothiazide) first before switching to a fixed-dose combination. However, current guidelines also support initiating treatment directly with a low-dose combination (such as telmisartan 40 mg/HCTZ 12.5 mg) in patients with moderate-to-severe hypertension or those with a high cardiovascular risk profile, as this strategy achieves blood pressure targets more rapidly.
Children and Adolescents
Actelsar HCT is not recommended for children and adolescents under 18 years of age. The safety and efficacy of telmisartan/hydrochlorothiazide combination in this population have not been established. For pediatric hypertension, other antihypertensive agents with established pediatric dosing and safety data should be used under specialist supervision.
Elderly Patients
No dose adjustment is generally required for elderly patients. However, older adults may be more susceptible to the hypotensive and electrolyte-altering effects of this medication due to age-related declines in renal function and reduced compensatory cardiovascular responses. Initiation of treatment should be gradual, with careful monitoring of blood pressure (including standing blood pressure to assess orthostatic changes), renal function, and electrolyte levels. Dehydration should be avoided, especially during hot weather or periods of illness.
Missed Dose
If you forget to take your daily dose of Actelsar HCT, take it as soon as you remember on the same day. If you do not remember until the next day, simply take your next scheduled dose at the usual time. Do not take a double dose to make up for the one you missed. Missing doses frequently can lead to suboptimal blood pressure control, so establishing a consistent routine (such as taking the tablet at the same time each morning) is important.
Overdose
An overdose of Actelsar HCT may cause symptoms related to the pharmacological effects of each component. Telmisartan overdose is expected to produce marked hypotension (dangerously low blood pressure) and tachycardia (fast heart rate), and potentially bradycardia (slow heart rate). Hydrochlorothiazide overdose may lead to severe electrolyte depletion (hypokalemia, hyponatremia, hypochloremia) and dehydration, with symptoms including nausea, vomiting, drowsiness, confusion, muscle cramps, dizziness, and excessive thirst.
There is no specific antidote for either component. Treatment is supportive and symptomatic: intravenous fluids for hypotension and dehydration, electrolyte replacement as guided by laboratory monitoring, and cardiovascular support as needed. Telmisartan is not significantly removed by hemodialysis. If overdose is suspected, seek emergency medical attention immediately or contact your local poison control center.
Always take Actelsar HCT exactly as prescribed by your doctor. Do not adjust the dose or stop taking the medication without medical advice, even if your blood pressure readings appear normal. High blood pressure rarely causes noticeable symptoms, so the medication is protecting you even when you feel perfectly well. Abrupt discontinuation may cause a rebound increase in blood pressure.
What Are the Side Effects of Actelsar HCT?
Like all medicines, Actelsar HCT can cause side effects, although not everybody gets them. The combination of telmisartan and hydrochlorothiazide at the doses used in Actelsar HCT is generally well tolerated. Side effects attributable to the combination as well as those known from each individual component are listed below, organized by frequency.
Side Effects of the Telmisartan/Hydrochlorothiazide Combination
Uncommon
May affect up to 1 in 100 people
- Dizziness
Rare
May affect up to 1 in 1,000 people
- Elevated serum uric acid levels (hyperuricemia)
- Low sodium levels (hyponatremia)
- Low potassium levels (hypokalemia)
- Elevated liver enzymes
- Impaired renal function including acute renal failure
Additional Side Effects Known from Telmisartan Alone
Uncommon
May affect up to 1 in 100 people
- Upper respiratory tract infections (including pharyngitis and sinusitis)
- Urinary tract infections
- Low red blood cell count (anemia)
- High potassium levels (hyperkalemia)
- Insomnia, depression, anxiety
- Fainting (syncope)
- Sensation of spinning (vertigo)
- Slow heart rate (bradycardia)
- Low blood pressure (hypotension), including orthostatic hypotension
- Shortness of breath (dyspnea), cough
- Abdominal pain, diarrhea, dry mouth, flatulence
- Abnormal liver function / liver disorder
- Itching (pruritus), increased sweating, skin rash
- Back pain, muscle spasms, muscle pain (myalgia)
- Kidney impairment
- Chest pain
- Elevated blood creatinine levels
Rare
May affect up to 1 in 1,000 people
- Sepsis (including fatal outcomes in rare cases)
- Low platelet count (thrombocytopenia)
- Allergic reactions (hypersensitivity, anaphylactic reaction)
- Disturbed vision
- Fast heart rate (tachycardia)
- Stomach discomfort, vomiting
- Eczema, drug eruption, toxic skin eruption
- Joint pain (arthralgia), pain in extremity, tendon pain
- Flu-like illness
- Decreased hemoglobin
Not Known
Frequency cannot be estimated from available data
- Angioedema (rapid swelling of face, lips, tongue, or throat – seek immediate medical attention)
- Erythema (skin redness)
- Urticaria (hives)
Additional Side Effects Known from Hydrochlorothiazide Alone
Common
May affect up to 1 in 10 people
- Electrolyte imbalances (especially hypokalemia at higher doses)
- Elevated blood lipids (cholesterol and triglycerides)
- Elevated uric acid levels
- Elevated blood glucose
Uncommon
May affect up to 1 in 100 people
- Loss of appetite, nausea, vomiting
- Skin rash, photosensitivity reactions
- Impotence
- Impaired renal function
- Glycosuria (sugar in urine)
Rare
May affect up to 1 in 1,000 people
- Low platelet count (thrombocytopenia), sometimes with bleeding
- Low white blood cell count (leukopenia)
- Allergic reactions (anaphylactic reactions)
- Elevated blood sugar progressing to diabetic coma
- Numbness or tingling (paresthesia)
- Visual disturbances, blurred vision, xanthopsia (yellow vision)
- Inflammation of blood vessels (vasculitis)
- Pneumonitis, pulmonary edema
- Pancreatitis
- Jaundice (cholestatic or intrahepatic)
- Lupus-like syndrome, photosensitivity
- Fever
- Weakness
Not Known
Frequency cannot be estimated from available data
- Aplastic anemia, hemolytic anemia, bone marrow depression
- Acute angle-closure glaucoma, acute myopia
- Severe skin reactions: toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS)
- Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) with cumulative long-term use
- Acute respiratory distress syndrome (ARDS)
- Metabolic alkalosis
Contact your doctor or go to the nearest emergency department immediately if you experience: swelling of the face, lips, tongue, or throat (angioedema); difficulty breathing or swallowing; severe dizziness or fainting; signs of severe allergic reaction (hives, rash spreading rapidly); sudden decrease in vision or eye pain; unusually fast, slow, or irregular heartbeat; or signs of severe electrolyte imbalance (persistent muscle cramps, confusion, seizures).
If you experience any side effects, including any not listed here, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Actelsar HCT?
Proper storage of your medication is important to ensure it remains effective and safe throughout its shelf life. Actelsar HCT tablets should be stored at a temperature not exceeding 25°C (77°F). Keep the tablets in the original blister packaging to protect them from moisture, as hydrochlorothiazide is sensitive to humidity. Do not store in the bathroom, as the humid environment can degrade the medication.
Keep this medicine out of the sight and reach of children. Store it in a secure location where children cannot access it. Do not use Actelsar HCT after the expiry date which is stated on the carton and blister after “EXP.” The expiry date refers to the last day of that month.
Do not dispose of medicines via household waste or wastewater. Ask your pharmacist about how to dispose of medicines you no longer use. These measures help protect the environment and prevent accidental ingestion by others.
What Does Actelsar HCT Contain?
The active substances in each Actelsar HCT 40 mg/12.5 mg tablet are:
- Telmisartan 40 mg: The angiotensin II receptor blocker (ARB) component. Telmisartan is a non-peptide, orally active, selective AT1 receptor antagonist with a high affinity for the angiotensin II type 1 receptor. It has the longest half-life among marketed ARBs (approximately 24 hours), which supports reliable 24-hour blood pressure control with once-daily dosing.
- Hydrochlorothiazide 12.5 mg: The thiazide diuretic component. Hydrochlorothiazide (HCTZ) has been in clinical use since 1958 and remains one of the most widely prescribed antihypertensive agents globally. The 12.5 mg dose provides meaningful blood pressure reduction while minimizing the dose-dependent metabolic side effects (such as hypokalemia, hyperglycemia, and hyperuricemia) that are more prominent at higher doses of 25–50 mg.
The other (inactive) ingredients include: povidone (K25), meglumine, sodium hydroxide, sorbitol (E420), magnesium stearate, lactose monohydrate, microcrystalline cellulose, maize starch, colloidal anhydrous silica, iron oxide red and/or yellow (E172), and hypromellose. Patients with hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine due to the lactose content. This medicine also contains sorbitol, which may affect patients with hereditary fructose intolerance.
Actelsar HCT 40 mg/12.5 mg tablets are biconvex, oval-shaped tablets. They are supplied in aluminum/aluminum blisters in cartons containing 14, 28, 56, or 98 tablets. Not all pack sizes may be marketed in your country.
Frequently Asked Questions About Actelsar HCT
Actelsar HCT is a combination medicine containing telmisartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). It is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is not adequately controlled by telmisartan or hydrochlorothiazide alone. By combining two different blood pressure-lowering mechanisms, Actelsar HCT provides more effective blood pressure control than either component used individually. Lowering blood pressure reduces the risk of cardiovascular events such as heart attack, stroke, and kidney damage.
No, Actelsar HCT must not be taken during pregnancy. Angiotensin II receptor blockers like telmisartan can cause serious harm to the developing fetus, including kidney damage, low amniotic fluid levels, and skull bone development problems. These risks are particularly significant during the second and third trimesters. If you become pregnant while taking Actelsar HCT, stop the medication immediately and contact your doctor. Women of childbearing potential should use effective contraception during treatment. If you are planning a pregnancy, your doctor will switch you to a safer alternative antihypertensive medication.
The most common side effect of the telmisartan/hydrochlorothiazide combination is dizziness, which occurs uncommonly (affecting fewer than 1 in 100 patients). Other possible side effects include low blood pressure (hypotension), electrolyte imbalances such as low potassium or sodium levels, increased uric acid levels, and digestive disturbances like diarrhea and nausea. The combination is generally well tolerated. Serious side effects are rare but include angioedema (severe swelling of the face or throat), acute kidney injury, and severe skin reactions. If you experience any unusual symptoms, consult your healthcare provider.
Alcohol can enhance the blood pressure-lowering effect of Actelsar HCT, which may cause excessive dizziness, lightheadedness, or fainting, especially when standing up. The hydrochlorothiazide component is particularly affected by alcohol consumption. It is advisable to limit or avoid alcohol consumption while taking this medication. If you do drink alcohol, do so in moderation and be aware of increased sensitivity to its effects. Stay well hydrated and change positions slowly (from sitting to standing) to minimize the risk of orthostatic hypotension. Discuss your alcohol consumption with your doctor.
Actelsar HCT begins lowering blood pressure within a few hours of the first dose. The hydrochlorothiazide component has a rapid onset of diuretic action (within 2 hours), while telmisartan reaches its full antihypertensive effect gradually over 4 to 8 weeks of regular use. The maximum blood pressure reduction with the combination is typically achieved within 4 to 8 weeks of consistent daily dosing. It is important to take the medication every day as prescribed, even if you feel well, as high blood pressure often has no noticeable symptoms. Do not stop taking Actelsar HCT without consulting your doctor, as uncontrolled blood pressure increases your risk of heart disease and stroke.
If you miss a dose of Actelsar HCT, take it as soon as you remember on the same day. If it is already close to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. If you frequently forget doses, consider setting a daily alarm or using a pill organizer to help maintain your routine. Consistent daily dosing is important for maintaining blood pressure control.
References
- European Medicines Agency (EMA). Actelsar HCT – Summary of Product Characteristics. EMA/HMPC, last updated 2025.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874–2071. doi:10.1097/HJH.0000000000003480
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–e248.
- World Health Organization (WHO). Guideline for the pharmacological treatment of hypertension in adults. WHO, 2021. Available at: who.int/publications/i/item/9789240033986
- Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–1357. doi:10.1161/HYPERTENSIONAHA.120.15026
- Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501–1529.
- Lacourcière Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Pressure Monitoring. 2004;9(4):203–210.
- ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine. 2008;358(15):1547–1559. doi:10.1056/NEJMoa0801317
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136], updated 2025.
- British National Formulary (BNF). Telmisartan with hydrochlorothiazide. NICE Evidence Services, 2026.
Medical Editorial Team
Medical Content
Written by iMedic Medical Writers – licensed healthcare professionals specializing in cardiovascular medicine and clinical pharmacology
Medical Review
Reviewed by iMedic Medical Review Board – board-certified physicians following ESH, AHA/ACC, and WHO guidelines
Fact-Checking
All medical claims verified against EMA SmPC, WHO guidelines, and peer-reviewed publications using GRADE evidence framework
Editorial Standards
Independent content with no pharmaceutical funding. Conflict of interest: none. View our editorial standards